HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology7 papers

Alexander disease type I

Last edited: 4/15/2026

Overview

Alexander disease type I, also known as I-cell disease, is a lysosomal storage disorder characterized by defective ganglioside and glycoprotein metabolism due to deficient neuraminidase activity, leading to severe systemic manifestations 1.

Diagnosis

  • Deficient neuraminidase activity in fibroblasts or leukocytes 1
  • Elevated levels of sialylated oligosaccharides in urine 1
  • Clinical presentation includes coarse facial features, hepatosplenomegaly, and developmental delay 1

    • Management

  • No specific curative treatment; management focuses on supportive care 1
  • Addressing complications such as infections and respiratory issues 1
  • Genetic counseling for families 1

    • Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1

    • Key Recommendations

  • Confirm diagnosis through biochemical testing including neuraminidase activity and urinary oligosaccharide analysis (Evidence: Weak) 1
  • Provide comprehensive supportive care tailored to individual symptoms and complications (Evidence: Expert opinion) 1
  • Offer genetic counseling to affected families for understanding inheritance patterns and risks (Evidence: Expert opinion) 1

    • References

    1 Milla PJ. I-cell disease. Archives of disease in childhood 1978. link

    Original source

    1. [1]
      I-cell disease. — Milla PJ Archives of disease in childhood (1978)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG